Track topics on Twitter Track topics that are important to you
TOKYO and LONDON, August 24, 2017 /PRNewswire/ -- Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) and Kyowa Kirin International PLC (Kyowa Kirin International), a wholly owned subsidiary of Kyowa ...
Kyowa Hakko Kirin Co. Ltd.MediaHiroki Nakamura, +firstname.lastname@example.org Read more...
Tokio (ots/PRNewswire) - Die Kyowa Hakko Kirin Co., Ltd. (Tokio: 4151 President und CEO: Nobuo Hanai, "Kyowa Hakko Kirin" gibt heute bekannt, dass ihr Vermarktungszulassungsantrag (MAA) für Mogamul.....
Japanese drugmaker Kyowa Hakko Kirin says it has discontinued the development of tivantinib (ARQ: 197),…
Friday, August 25th 2017 at 6:30am UTC TOKYO–(BUSINESS WIRE)– Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151)(President and CEO: Nobuo Hanai, “Kyowa Hakko Kirin”) today announced that U.S. Fo...
Kyowa Hakko Kirin Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Kyowa Hakko Kirin Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances an...
Kyowa Hakko Kirin's mogamulizumab, indicated for the treatment of mycosis fungoides and Sezary syndrome, was granted breakthr -More-
Shares in Japan’s Kyowa Hakko Kirin are up nearly 4% following news that the company will proceed next…
From its foundation in 1949, Kyowa Hakko has been a global leader in the pharmaceutical industry. Today, Kyowa's expertise extends to the United States through Kyowa Pharmaceutical, Inc. headquartered...
We have published hundreds of Kyowa Hakko USA news stories on BioPortfolio along with dozens of Kyowa Hakko USA Clinical Trials and PubMed Articles about Kyowa Hakko USA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kyowa Hakko USA Companies in our database. You can also find out about relevant Kyowa Hakko USA Drugs and Medications on this site too.